Research ExplorerPublicationsAssessment of the VENUSS and GRANT Models for Individual Pre...

Assessment of the VENUSS and GRANT Models for Individual Prediction of Cancer-specific Survival in Surgically Treated Nonmetastatic Papillary Renal Cell Carcinoma

Standard

Assessment of the VENUSS and GRANT Models for Individual Prediction of Cancer-specific Survival in Surgically Treated Nonmetastatic Papillary Renal Cell Carcinoma. / Piccinelli, Mattia L; Tappero, Stefano; Cano Garcia, Cristina; Barletta, Francesco; Incesu, Reha-Baris; Morra, Simone; Scheipner, Lukas; Tian, Zhe; Luzzago, Stefano; Mistretta, Francesco A; Ferro, Matteo; Saad, Fred; Shariat, Shahrokh F; Ahyai, Sascha; Longo, Nicola; Tilki, Derya; Briganti, Alberto; Chun, Felix K H; Terrone, Carlo; de Cobelli, Ottavio; Musi, Gennaro; Karakiewicz, Pierre I.

In: EUR UROL OPEN SCI, Vol. 53, 07.2023, p. 109-115.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Piccinelli, ML, Tappero, S, Cano Garcia, C, Barletta, F, Incesu, R-B, Morra, S, Scheipner, L, Tian, Z, Luzzago, S, Mistretta, FA, Ferro, M, Saad, F, Shariat, SF, Ahyai, S, Longo, N, Tilki, D, Briganti, A, Chun, FKH, Terrone, C, de Cobelli, O, Musi, G & Karakiewicz, PI 2023, 'Assessment of the VENUSS and GRANT Models for Individual Prediction of Cancer-specific Survival in Surgically Treated Nonmetastatic Papillary Renal Cell Carcinoma', EUR UROL OPEN SCI, vol. 53, pp. 109-115. https://doi.org/10.1016/j.euros.2023.05.005

APA

Piccinelli, M. L., Tappero, S., Cano Garcia, C., Barletta, F., Incesu, R-B., Morra, S., Scheipner, L., Tian, Z., Luzzago, S., Mistretta, F. A., Ferro, M., Saad, F., Shariat, S. F., Ahyai, S., Longo, N., Tilki, D., Briganti, A., Chun, F. K. H., Terrone, C., ... Karakiewicz, P. I. (2023). Assessment of the VENUSS and GRANT Models for Individual Prediction of Cancer-specific Survival in Surgically Treated Nonmetastatic Papillary Renal Cell Carcinoma. EUR UROL OPEN SCI, 53, 109-115. https://doi.org/10.1016/j.euros.2023.05.005

Vancouver

Piccinelli ML, Tappero S, Cano Garcia C, Barletta F, Incesu R-B, Morra S et al. Assessment of the VENUSS and GRANT Models for Individual Prediction of Cancer-specific Survival in Surgically Treated Nonmetastatic Papillary Renal Cell Carcinoma. EUR UROL OPEN SCI. 2023 Jul;53:109-115. https://doi.org/10.1016/j.euros.2023.05.005

Bibtex

@article{fba6a6aeb53e4138adac99e7a18d8d60,
title = "Assessment of the VENUSS and GRANT Models for Individual Prediction of Cancer-specific Survival in Surgically Treated Nonmetastatic Papillary Renal Cell Carcinoma",
abstract = "BACKGROUND: Guidelines recommend VENUSS and GRANT models for the prediction of cancer control outcomes after nephrectomy for nonmetastatic papillary renal cell carcinoma (pRCC).OBJECTIVE: To test the ability of VENUSS and GRANT models to predict 5-yr cancer-specific survival in a North American population.DESIGN SETTING AND PARTICIPANTS: For this retrospective study, we identified 4184 patients with unilateral surgically treated nonmetastatic pRCC in the Surveillance, Epidemiology, and End Results database (2004-2019).OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The original VENUSS and GRANT risk categories were applied to predict 5-yr cancer-specific survival. A cross-validation method was used to test the accuracy and calibration of the models and to conduct decision curve analyses for the study cohort.RESULTS AND LIMITATIONS: The VENUSS and GRANT categories represented independent predictors of cancer-specific mortality. On cross-validation, the accuracy of the VENUSS and GRANT risk categories was 0.73 and 0.65, respectively. Both models showed good calibration and performed better than random predictions in decision curve analysis. Limitations include the retrospective nature of the study and the absence of a central pathological review.CONCLUSION: VENUSS risk categories fulfilled prognostic model criteria for predicting cancer-specific survival 5 yr after surgery in North American patients with nonmetastatic pRCC as recommended by guidelines. Conversely, GRANT risk categories did not. Thus, VENUSS risk categories represent an important tool for counseling, follow-up planning, and patient selection for appropriate adjuvant trials in pRCC.PATIENT SUMMARY: We tested the ability of two validated methods (VENUSS and GRANT) to predict death due to papillary kidney cancer in a North American population. The VENUSS risk categories showed good performance in predicting 5-year cancer-specific survival.",
author = "Piccinelli, {Mattia L} and Stefano Tappero and {Cano Garcia}, Cristina and Francesco Barletta and Reha-Baris Incesu and Simone Morra and Lukas Scheipner and Zhe Tian and Stefano Luzzago and Mistretta, {Francesco A} and Matteo Ferro and Fred Saad and Shariat, {Shahrokh F} and Sascha Ahyai and Nicola Longo and Derya Tilki and Alberto Briganti and Chun, {Felix K H} and Carlo Terrone and {de Cobelli}, Ottavio and Gennaro Musi and Karakiewicz, {Pierre I}",
note = "{\textcopyright} 2023 The Authors.",
year = "2023",
month = jul,
doi = "10.1016/j.euros.2023.05.005",
language = "English",
volume = "53",
pages = "109--115",
journal = "EUR UROL OPEN SCI",
issn = "2666-1691",
publisher = "Elsevier BV",

}

RIS

TY - JOUR

T1 - Assessment of the VENUSS and GRANT Models for Individual Prediction of Cancer-specific Survival in Surgically Treated Nonmetastatic Papillary Renal Cell Carcinoma

AU - Piccinelli, Mattia L

AU - Tappero, Stefano

AU - Cano Garcia, Cristina

AU - Barletta, Francesco

AU - Incesu, Reha-Baris

AU - Morra, Simone

AU - Scheipner, Lukas

AU - Tian, Zhe

AU - Luzzago, Stefano

AU - Mistretta, Francesco A

AU - Ferro, Matteo

AU - Saad, Fred

AU - Shariat, Shahrokh F

AU - Ahyai, Sascha

AU - Longo, Nicola

AU - Tilki, Derya

AU - Briganti, Alberto

AU - Chun, Felix K H

AU - Terrone, Carlo

AU - de Cobelli, Ottavio

AU - Musi, Gennaro

AU - Karakiewicz, Pierre I

N1 - © 2023 The Authors.

PY - 2023/7

Y1 - 2023/7

N2 - BACKGROUND: Guidelines recommend VENUSS and GRANT models for the prediction of cancer control outcomes after nephrectomy for nonmetastatic papillary renal cell carcinoma (pRCC).OBJECTIVE: To test the ability of VENUSS and GRANT models to predict 5-yr cancer-specific survival in a North American population.DESIGN SETTING AND PARTICIPANTS: For this retrospective study, we identified 4184 patients with unilateral surgically treated nonmetastatic pRCC in the Surveillance, Epidemiology, and End Results database (2004-2019).OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The original VENUSS and GRANT risk categories were applied to predict 5-yr cancer-specific survival. A cross-validation method was used to test the accuracy and calibration of the models and to conduct decision curve analyses for the study cohort.RESULTS AND LIMITATIONS: The VENUSS and GRANT categories represented independent predictors of cancer-specific mortality. On cross-validation, the accuracy of the VENUSS and GRANT risk categories was 0.73 and 0.65, respectively. Both models showed good calibration and performed better than random predictions in decision curve analysis. Limitations include the retrospective nature of the study and the absence of a central pathological review.CONCLUSION: VENUSS risk categories fulfilled prognostic model criteria for predicting cancer-specific survival 5 yr after surgery in North American patients with nonmetastatic pRCC as recommended by guidelines. Conversely, GRANT risk categories did not. Thus, VENUSS risk categories represent an important tool for counseling, follow-up planning, and patient selection for appropriate adjuvant trials in pRCC.PATIENT SUMMARY: We tested the ability of two validated methods (VENUSS and GRANT) to predict death due to papillary kidney cancer in a North American population. The VENUSS risk categories showed good performance in predicting 5-year cancer-specific survival.

AB - BACKGROUND: Guidelines recommend VENUSS and GRANT models for the prediction of cancer control outcomes after nephrectomy for nonmetastatic papillary renal cell carcinoma (pRCC).OBJECTIVE: To test the ability of VENUSS and GRANT models to predict 5-yr cancer-specific survival in a North American population.DESIGN SETTING AND PARTICIPANTS: For this retrospective study, we identified 4184 patients with unilateral surgically treated nonmetastatic pRCC in the Surveillance, Epidemiology, and End Results database (2004-2019).OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The original VENUSS and GRANT risk categories were applied to predict 5-yr cancer-specific survival. A cross-validation method was used to test the accuracy and calibration of the models and to conduct decision curve analyses for the study cohort.RESULTS AND LIMITATIONS: The VENUSS and GRANT categories represented independent predictors of cancer-specific mortality. On cross-validation, the accuracy of the VENUSS and GRANT risk categories was 0.73 and 0.65, respectively. Both models showed good calibration and performed better than random predictions in decision curve analysis. Limitations include the retrospective nature of the study and the absence of a central pathological review.CONCLUSION: VENUSS risk categories fulfilled prognostic model criteria for predicting cancer-specific survival 5 yr after surgery in North American patients with nonmetastatic pRCC as recommended by guidelines. Conversely, GRANT risk categories did not. Thus, VENUSS risk categories represent an important tool for counseling, follow-up planning, and patient selection for appropriate adjuvant trials in pRCC.PATIENT SUMMARY: We tested the ability of two validated methods (VENUSS and GRANT) to predict death due to papillary kidney cancer in a North American population. The VENUSS risk categories showed good performance in predicting 5-year cancer-specific survival.

U2 - 10.1016/j.euros.2023.05.005

DO - 10.1016/j.euros.2023.05.005

M3 - SCORING: Journal article

C2 - 37441347

VL - 53

SP - 109

EP - 115

JO - EUR UROL OPEN SCI

JF - EUR UROL OPEN SCI

SN - 2666-1691

ER -